Poxviruses as expression vectors

Current Opinion in Biotechnology

Volumn 8, Issue 5, 1997, Pages 573-577

  Carroll, Miles W ^a   Moss, Bernard ^b  

^a OXFORD BIOMEDICA UK LTD   (United Kingdom)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPSTEIN BARR VIRUS VACCINE; LIVE VACCINE; RNA POLYMERASE;

BACTERIOPHAGE T7; CLINICAL TRIAL; CYTOTOXICITY; EXPRESSION VECTOR; GENE EXPRESSION; HUMAN; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PROMOTER REGION; RECOMBINANT GENE; SHORT SURVEY; VACCINIA VIRUS; VIRUS INFECTION; VIRUS MUTANT; VIRUS RECOMBINANT; VIRUS REPLICATION;

HUMAN HERPESVIRUS 4; MAMMALIA; POXVIRIDAE; VACCINIA; VACCINIA VIRUS;

EID: 0030696246     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(97)80031-6     Document Type: Article

References (52)

1. Moss B: Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996, 93:11341-11348. A recent review of replicating and non-replicating poxvirus vectors that provides numerous references omitted from the present summary. Includes some background information on the biological properties of poxviruses as related to their use as vectors.
2. Paoletti E: Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci USA 1996, 93:11349-11353. A recent review primarily of non-replicating poxvirus vectors developed as vaccine candidates by the author and collaborators.
3. Flexner C, Moss B: Vaccinia virus as a live vector for expression of immunogens. In New Generation Vaccines, 2nd edn. Edited by Levine MM, Woodrow GC, Kaper JB, Cobon GS. New York: Marcel Dekker; 1997:297-314. An extensive review of recombinant vaccinia virus vectors, listing many that have been used for expression of immunogens in animal models.
4. Mackett M, Smith GL, Moss B: A selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA 1982, 79:7415-7419.
5. Panicali D, Paoletti E: Construction of poxviruses as cloning vectors: insertion of the TK gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci USA 1982, 79:4927-4931.
6. Earl PL, Moss B: Generation of recombinant vaccinia viruses. In Current Protocols in Molecular Biology. Edited by Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K. New York: Greene Publishing Associates & Wiley Interscience; 1991:16.17.1-16.17.16.
7. Carroll MW, Moss B: E. coli β-glucuronidase (GUS) as a marker for recombinant vaccinia viruses. Bio-Techniques 1995, 19:352-355.
8. Howley PM, Spehner D, Drillien R: A vaccinia virus transfer vector using a GUS reporter gene inserted into the 14L locus. Gene 1996, 172:233-237.
9. Cao J, Upton C: gpt-gus fusion gene for selection and marker in recombinant poxviruses. Bio-Techniques 1997, 22:276-278.
10. Wu G-Y, Zou D-J, Cline HT: Infection of frog neurons with vaccinia virus permits in vivo expression of foreign proteins. Neuron 1995, 14:681-684.
11. Blasco R, Moss B: Selection of recombinant vaccinia viruses on the basis of plaque formation. Gene 1995, 158:157-162.
12. Falkner FG, Moss B: Transient dominant selection of recombinant vaccinia viruses. J Virol 1990, 64:3108-3111.
13. Isaacs SN, Kotwal GJ, Moss B: Reverse guanine phosphoribosyltransferase selection of recombinant vaccinia viruses. Virology 1990, 178:626-630.
14. Spehner D, Drillien R, Lecocq J-P: Construction of fowlpox virus vectors with intergenic insertions: expression of the β-galactosidase gene and measles virus fusion gene. J Virol 1990, 64:527-533.
15. Kurilla MG: Transient selection during vaccinia virus recombination with insertion vectors without selectable markers. Bio-Techniques 1997, 22:906-910.
16. Pfleiderer M, Falkner FG, Dorner F: A novel vaccinia virus expression system allowing construction of recombinants without the need for selection markers, plasmids and bacterial hosts. J Gen Virol 1995, 76:2957-2962.
17. Merchlinsky M, Eckert D, Smith E, Zauderer M: Construction and characterisation of vaccinia direct ligation vectors. Virology 1997, in press.
18. Moss B: Poxviridae: the viruses and their replication. In Fields Virology. Edited by Fields BN, Knipe DM, Howley PM. Philadelphia: Lippincott-Raven Publishers; 1996:2637-2671. This introduction to the biology of poxviruses is recommended to anyone using poxvirus vectors.
19. Wyatt LS, Shors ST, Murphy BR, Moss B: Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 1996, 14:1451-1458. Comparison of strengths of several early/late promoters. Demonstrates immunogenicity of recombinant modified vaccinia virus Ankara by intranasal and intramuscular routes.
20. Chakrabarti C, Sisler JR, Moss B: A compact synthetic vaccinia virus early/late promoter for protein expression. Biotechniques 1997, in press.
21. Holzer G, Falkner FG: Construction of a vaccinia virus deficient in the essential DNA repair enzyme uracil DNA glycosylase by a complementing cell line. J Virol 1997, 71:4997-5002. The authors stably transfected a cell line with the vaccinia virus uracil DNA glycoslylase gene, encoding an enzyme required for viral DNA replication. The cells were then used to isolate and propagate a mutant vaccinia virus with a deleted uracil DNA glycosylase gene. In non-permissive cells, prolonged early gene expression was detected, suggesting the potential of the mutant virus as an expression vector.
22. Tsung K, Yim JH, Marti W, Buller RML, Norton JA: Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light. J Virol 1995, 70:165-171.
23. Ward GA, Stover CK, Moss B, Fuerst TR: Stringent chemical and thermal regulation of recombinant gene expression by vaccinia virus vectors in mammalian cells. Proc Natl Acad Sci USA 1995, 92:6773-6777.
24. Ramsey-Ewing A, Moss B: Recombinant protein synthesis in CHO cells using a vaccinia virus/bacteriophage T7 hybrid expression system. J Biol Chem 1996, 271:16962-16966.
25. Wyatt LS, Moss B, Rozenblatt S: Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology 1995, 210:202-205.
26. Sutter G, Ohlmann M, Erfle V: Non-replicating vaccinia vector efficiently expresses bacteriophage T7 RNA polymerase. FEBS Lett 1995, 371:9-12.
27. Hu L, Esposito JJ, Scott FW: Raccoon poxvirus feline panleukopenia virus VP2 recombinant protects cats against FPV challenge. Virology 1996, 218:248-252.
28. Kochneva GV, Urmanov IH, Ryabchikova EI, Streltsov W, Serpinsky OI: Fine mechanisms of ectromelia virus thymidine kinase-negative mutants avirulence. Virus Res 1994, 34:49-61.
29. Romero CH, Barrett T, Chamberlain RW, Kitching RP, Fleming M, Black DN: Recombinant capripoxvirus expressing the hemagglutinin protein gene of rinderpest virus: protection of cattle against rinderpest and lumpy skin disease. Virology 1994, 204:425-429.
30. Jackson RJ, Hall DF, Kerr PJ: Construction of recombinant myxoma viruses expressing genes from different intergenic sites without associated attenuation. J Gen Virol 1996, 77:1569-1575.
31. Somogyi P, Frazier J, Skinner MA: Fowlpox virus host range restriction: gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells. Virology 1993, 197:439-444.
32. Britton P, Green P, Kottier S, Mawditt KL, Penzes Z, Cavanaugh D, Skinner MA: Expression of bacteriophage T7 RNA polymerase in avian and mammalian cells by a recombinant fowlpox virus. J Gen Virol 1996, 77:963-967.
33. Feng Y, Broder CC, Kennedy PE, Berger EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane G protein-coupled receptor. Science 1996, 272:872-877. Outstanding example of the use of the bacteriophage T7-vaccinia virus expression system for screening a cDNA library. This paper describes the discovery of an HIV-1 coreceptor molecule.
34. Hoffman MA, Banerjee AK: An infectious clone of human parainfluenza virus type 3. J Virol 1997, 71:4272-4277.
35. Bridgen A, Elliott RM: Rescue of a segmented negative-strand RNA virus entirely from cloned complementary DNAs. Proc Natl Acad Sci USA 1996, 93:15400-15404. The first report of an infectious segmented RNA virus formed from cDNA. The bacteriophage T7-vaccinia virus expression system was used.
36. Petit DL, Koothan T, Liao D, Malinow R: Vaccinia virus transfection of hippocampal slices. Neuron 1995, 14:685-688.
37. Katz E, Wolffe EJ, Moss B: The cytoplasmic and transmembrane domains of the vaccinia virus B5R protein target a chimeric human immunodeficiency virus type 1 glycoprotein to the outer envelope of nascent vaccinia virions. J Virol 1997, 71:3178-3187. The first report of the presentation of a recombinant protein on the surface of vaccinia virus particles. Further work along these lines may lead to targeting of virus particles to specific cells.
38. Brochier B, Costy F, Pastoret PP: Elimination of fox rabies from Belgium using a recombinant vaccinia-rabies vaccine: an update. Vet Microbiol 1995, 46:269-279.
39. Hirsch VM, Fuerst TR, Sutter G, Carroll MW, Yang LC, Goldstein S, Piatak M Jr, Elkins WR, Alvord WG, Montefiori DC et al.: Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol 1996, 70:3741-3752.
40. Myagkikh M, Alpanah S, Markham PD, Tartaglia J, Paoletti E, Gallo RC, Franchini G, Robert-Guroff M: Multiple immunizations with attenuated poxvirus HIV type 2 rcombinants and subunit boosts required for protection of rhesus macaques. AIDS Res Human Retoviruses 1996, 12:985-992.
41. Bender BS, Rowe CA, Taylor F, Wyatt LS, Moss B, Small PA: Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J Virol 1996, 70:6418-6424.
42. Gu SY, Huang TM, Ruan L, Miao YH, Lu H, Chu CM, Motz M, Wolf H: First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand 1995, 84:171-177.
43. Fries LF, Tartaglia J, Taylor J, Kauffman EK, Meignier B, Paoletti E, Plotkin S: Human safety and immunogenicity of a canarypoxrabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine 1996, 14:428-434. Documentation of the safety and immunogenicity of canarypox vector as a vaccine candidate.
44. Bronte V, Carroll MW, Goletz TJ, Wang M, Overwijk WW, Marincola F, Rosenberg SA, Moss B, Restifo NP: Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci USA 1997, 93:3183-3188. This study demonstrates that early expression of tumour antigens is necessary for tumour immunotherapy and antigen presentation. Best results were obtained using a strong synthetic early/late promoter.
45. Wang M, Bronte V, Chen PW, Gritz L, Panicali D, Rosenberg SA, Restifo NP: Active immunotherapy of cancer with a non- replicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol 1995, 154:4685-4692.
46. Roth J, Dittmer D, Rea D, Tartaglia J, Paoletti E, Levine AJ: p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci USA 1996, 93:4781-4786.
47. Carroll MW, Overwiijk WW, Chamberlain RS, Rosenberg SA, Moss B, Restifo NP: Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 1997, 15:387-394.
48. Hodge JW, Abrams S, Schlom J, Kantor JA: Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 co-stimulatory molecules. Cancer Res 1995, 54:5552-5555.
49. Bronte V, Tsung K, Rao JB, Chen PW, Wang M, Rosenberg SA, Restifo NP: IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol 1995, 154:5282-5292.
50. Chamberlain RS, Carroll MW, Bronte V, Hwu P, Warren S, Yang JC, Nishimura M, Moss B, Rosenberg SA, Restifo NP: Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res 1996, 56:2832-2836.
51. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, Evans AS, Adams M, Stacey SN, Boursnell ME et al.: A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996, 347:1523-1527.
52. McAneny D, Ryan CA, Beazley RM, Kaufman HL: Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann Surg Oncol 1996, 3:495-500.